Claims
- 1. A compound of formula (1): ##STR62## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a halogen atom, a nitro group, a carboxyl group, an alkoxycarbonyl group, an aromatic group, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --CON(R.sub.6)R.sub.7, --SO.sub.2 N(R.sub.6)R.sub.7, --S(O).sub.n R.sub.8 wherein R.sub.8 is an unsubstituted alkyl group, a substituted alkyl group or an aromatic group, and n is an integer of 0, 1 or 2, --Q--Ra, or ##STR63## wherein A is an oxygen atom, --S(O).sub.n -- wherein n is as defined above or --N(R.sub.10)--, R.sub.9 is a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, an acyl group or --Q--Ra, and the ring is a 3- to 8-membered saturated heterocyclic group composed of a nitrogen atom and carbon atoms;
- Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y.sub.6 and Y.sub.7, which may be the same or different, are independently a single bond, --CH.sub.2 --, --CO--, --C(.dbd.C(R.sub.11)R.sub.12)-- or adjacent members of a group consisting of Y.sub.1 through Y.sub.7 being able to be taken together to represent --CH.dbd.CH--, and three of Y.sub.1 through Y.sub.7 being independently a single bond,
- Z may be absent, or one or more Zs may be present and are, the same or different, independently the following substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.7 ; an unsubstituted alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a halogen atom, a carboxyl group, an alkoxycarbonyl group, an aromatic group, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --S(O).sub.n R.sub.8, --C(O)N(R.sub.6)R.sub.7, or --Q--Ra, provided that when Z is a substituent for the hydrogen atom of --CH.dbd.CH--, Z is not --N(R.sub.6)R.sub.7 or --S(O).sub.n R.sub.8 ;
- Q is a substituted or unsubstituted lower alkylene group;
- Ra is a substituted or unsubstituted vinyl group, or a substituted or unsubstituted ethynyl group;
- R.sub.5 is a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group or an aromatic group;
- R.sub.6 and R.sub.7 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, an aromatic group, an acyl group or --Q--Ra, or R.sub.6 and R.sub.7, when taken together with the nitrogen atom to which they are bonded, form a saturated 5- to 7-membered cyclic amino group which may contain an oxygen atom or a sulfur atom in the ring and may be substituted by one or more unsubstituted alkyl groups, substituted alkyl groups, hydroxyl groups or --OR.sub.5 groups;
- R.sub.8 is an unsubstituted alkyl group, a substituted alkyl group or an aromatic group;
- R.sub.10 is a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a cycloalkyl group, a saturated heterocyclic group, an aromatic group, an acyl group or --Q--Ra; and
- R.sub.11 and R.sub.12 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a halogen atom, a carboxyl group, an alkoxycarbonyl group, an aromatic group, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --CON(R.sub.6)R.sub.7, --S(O).sub.n R.sub.8 or --Q--Ra or a pharmaceutically acceptable acid addition salt thereof.
- 2. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom, a nitro group, an aromatic group, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --CON(R.sub.6)R.sub.7, --SO.sub.2 N(R.sub.6)R.sub.7, --S(O).sub.n R.sub.8 or --Q--Ra wherein Ra is a substituted or unsubstituted vinyl group.
- 3. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, wherein R.sub.1 is a hydrogen atom.
- 4. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --CON(R.sub.6)R.sub.7, --SO.sub.2 N(R.sub.6)R.sub.7, or --S(O).sub.n R.sub.8.
- 5. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, wherein Z may be absent, or one or more Zs may be present and are, the same or different, independently the following substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.7 : an unsubstituted alkyl group, a substituted alkyl group, an alkenyl group, a cycloalkyl group, a saturated heterocyclic group, a carboxyl group, an aromatic group, an acyl group, --OR.sub.5, --N(R.sub.6)R.sub.7, --S(O).sub.n R.sub.8, or --C(O)N(R.sub.6)R.sub.7, provided that when Z is a substituent for the hydrogen atom of --CH.dbd.CH--, Z is not --N(R.sub.6)R.sub.7 or --S(O).sub.n R.sub.8.
- 6. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, 2, 3, 4, or 5, wherein one of Y.sub.1 through Y.sub.7 is --CH.sub.2 --, --CO-- or --C(.dbd.C(R.sub.11)R.sub.12)--, another is --CH.sub.2 --, and the five others, which may be the same or different, are independently a single bond or --CH.sub.2 --, and Z is as defined in claim 1.
- 7. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 6, wherein Y.sub.1 is --CH.sub.2 --, --CO-- or --C(.dbd.C(R.sub.11)R.sub.12)--, Y.sub.2 is --CH.sub.2 --, Y.sub.3 through Y.sub.7, which may be the same or different, are independently a single bond or --CH.sub.2 --, and Z is as defined in claim 1.
- 8. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 6, wherein Y.sub.7 is --CO-- or --C(.dbd.C(R.sub.11)R.sub.12)--, Y.sub.6 is --CH.sub.2 --, Y.sub.1 through Y.sub.3, which may be the same or different, are independently a single bond or --CH.sub.2 --, and Z is as defined in claim 1.
- 9. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, 2, 3, 4 or 5 wherein any adjacent two members of a group consisting of Y.sub.1 through Y.sub.6 are taken together to represent --CH.dbd.CH--, the four others, which may be the same or different, are independently a single bond or --CH.sub.2 --, Y.sub.7 is a single bond, --CO--, --C(.dbd.C(R.sub.11)R.sub.12)-- or --CH.sub.2 --, and Z is as defined in claim 1.
- 10. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 7, wherein --Y.sub.1 --Y.sub.2 -- is --CH.dbd.CH--, and Z is as defined in claim 1.
- 11. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1 or 2, wherein one of Y.sub.2 through Y.sub.7 is --CO--, the five others, which may be the same or different, are independently a single bond or --CH.sub.2 --, and Z is as defined in claim 1.
- 12. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 11, wherein Y.sub.2 is --CO--, and Z is as defined in claim 1.
- 13. A process for producing a compound of the formula (1) or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which comprises reacting a compound represented by the formula (2): ##STR64## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y.sub.6, Y.sub.7 and Z are as defined in claim 1, and J is a leaving group replaceable by a nucleophilic reagent, with guanidine.
- 14. A pharmaceutical composition comprising a compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to any one of claims 1 to 5 as an active ingredient.
- 15. A pharmaceutical composition according to claim 14, wherein the composition is for inhibiting a sodium/proton exchange transport system.
- 16. A pharmaceutical composition according to claim 14, wherein the composition is for the treatment or prophylaxis of hyperpiesia, arrhythmia, angina pectoris, hypercardia, diabetes, organopathies due to ischemia or ischemia re-perfusion, troubles due to cerebral ischemia, a disease caused by cell over-proliferations, or a disease caused by trouble with endothelial cells.
- 17. A compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to any of claims 1-5 for use as an active ingredient of a pharmaceutical composition.
- 18. A method for treating or preventing a disease caused by accelerated sodium/proton exchange transport system, which comprises administering an effective amount of a compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof according to any one of claims 1-5 to an animal including a human being.
- 19. A method for treating or preventing a disease according to claim 18, wherein the disease is selected from the group consisting of: hyperpiesia, arrhythmia, angina pectoris, hypercardia, diabetes, organopathies due to ischemia or ischemia re-perfusion, troubles due to cerebral ischemia, diseases caused by cell over-proliferations, and diseases caused by trouble with endothelial cells.
Priority Claims (4)
Number |
Date |
Country |
Kind |
8-040611 |
Feb 1996 |
JPX |
|
8-131370 |
Apr 1996 |
JPX |
|
8-219322 |
Jul 1996 |
JPX |
|
8-356301 |
Dec 1996 |
JPX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/790,024 filed Jan. 28, 1997.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4567177 |
Bigg et al. |
Jan 1986 |
|
5814654 |
Kitano et al. |
Sep 1998 |
|
Foreign Referenced Citations (20)
Number |
Date |
Country |
3301493 |
Aug 1993 |
AUX |
3301593 |
Aug 1993 |
AUX |
6884494 |
Feb 1995 |
AUX |
8170094 |
Jun 1995 |
AUX |
1635495 |
Oct 1995 |
AUX |
1786195 |
Nov 1995 |
AUX |
3025195 |
Feb 1996 |
AUX |
3014495 |
Mar 1996 |
AUX |
3025095 |
Mar 1996 |
AUX |
2172095 |
Apr 1996 |
AUX |
0322016 |
Jun 1989 |
EPX |
0386628 |
Sep 1990 |
EPX |
0387618 |
Sep 1990 |
EPX |
0620221 |
Oct 1994 |
EPX |
0622356 |
Nov 1994 |
EPX |
0639573 |
Feb 1995 |
EPX |
0708091 |
Apr 1996 |
EPX |
0719766 |
Jul 1996 |
EPX |
0726254 |
Aug 1996 |
EPX |
9426709 |
Nov 1994 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Journal of the American Chemical Society, vol. 80, No. 20, Oct. 20, 1958, pp. 5574-5575. |
Khim. Geterotsikl. Soedin., No. 6, 1979, pp. 839-841. |
Khim. Geterotsikl. Soedin., No. 7, 1981, pp. 983-986. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
790024 |
Jan 1997 |
|